- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001890
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
Immunomodulatory Effects of Hormone Therapy in Postmenopausal Women With Chronic Chlamydia Pneumoniae or Cytomegalovirus Infection
Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases. These findings suggest that estrogen may be protective and help in preventing heart disease.
Studies of large groups of post-menopausal women suggest that hormone replacement therapy (therapy that includes estrogen) reduces the risk of heart disease. Estrogen causes favorable changes in particles that carry cholesterol in the blood stream and improves function of blood vessels. Estrogen may also stimulate the immune system's ability to fight off infections that may lead to or contribute to atherosclerosis.
Researchers believe two specific infectious agents (Chlamydia pneumoniae and human cytomegalovirus) may cause damage to the lining of blood vessels resulting in inflammation and the development of atherosclerosis.
The purpose of this study is to determine if estrogen treatment can change how the immune system responds to chronic infections, by Chlamydia pneumoniae and human cytomegalovirus, in postmenopausal women.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Heart, Lung and Blood Institute (NHLBI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Must be a postmenopausal woman 65 years of age or younger.
Time since last date of menses should be at least 12 months, with plasma estradiol less than 50 pg/ml and FSH greater than 50 pg/ml.
Women must be without clinical evidence of CAD as determined by history, cardiovascular physical examination, and EKG.
Must not have used hormone replacement therapy within past 6 months.
Must not have used dietary supplements and any medication (over-the-counter or prescribed) within 1 month. Acetaminophen use is allowed.
Must not have a history of alcoholism or binge-drinking.
Must not have diabetes mellitus or known abnormal glucose intolerance test.
Must not have a history of stroke, angina or myocardial infarction.
Must not have a history of deep venous thrombosis/pulmonary embolism.
Must not have a history of cancer (except for treated squamous cell and basal cell carcinomas).
Must not have evidence of liver disease (liver function enzymes greater than twice the upper limit of normal).
Must not have impaired renal function (creatinine greater than 1.6 mg/dl).
Must not have a diagnosis of an autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, thyroiditis, Raynaud's Disease).
Must not have a history of intermittent vaginal bleeding.
Must not have serum triglycerides greater than 400 mg/dL.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Publications and helpful links
General Publications
- Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801-9. doi: 10.1038/362801a0.
- Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997 Aug 9;350(9075):430-6. doi: 10.1016/S0140-6736(97)03079-1.
- Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996 May;64(5):1614-20. doi: 10.1128/iai.64.5.1614-1620.1996.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Sexually Transmitted Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Lung Diseases
- Disease Attributes
- DNA Virus Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Herpesviridae Infections
- Chlamydiaceae Infections
- Sexually Transmitted Diseases, Bacterial
- Infections
- Communicable Diseases
- Pneumonia
- Atherosclerosis
- Pneumonia, Bacterial
- Cytomegalovirus Infections
- Chlamydia Infections
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
Other Study ID Numbers
- 990100
- 99-H-0100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on Estrogen therapy
-
National Heart, Lung, and Blood Institute (NHLBI)Wake Forest University Health SciencesCompleted
-
Intarcia TherapeuticsTerminatedBreast Neoplasms | Neoplasms, Hormone-DependentUnited States, Romania, Russian Federation, Ukraine, Bulgaria
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology; NCIC Clinical Trials Group; Cancer...CompletedRadiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in SituBreast CancerUnited States, Canada
-
University of Southern CaliforniaNational Institute on Aging (NIA)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)Completed
-
Intarcia TherapeuticsCompletedBreast Neoplasms | Neoplasms, Hormone-dependentUnited States, Canada, Russian Federation, Ukraine
-
Centre Francois BaclesseNational Cancer Institute, France; ARC Foundation for Cancer ResearchTerminatedMetastatic Breast Cancer | PostmenopausalFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMammographically Dense BreastUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States, Canada
-
Cedars-Sinai Medical CenterUnknown